What’s New in Dangerous Product Lawsuits in November 2026
It’s been another busy month for some of the largest dangerous product lawsuits in the country.
From a critical FDA decision that impacts millions of Americans to a pending weed killer settlement, here are some of the biggest updates from the last few weeks to keep an eye on.
Ozempic, Other GLP-1s Must Warn Users of Blindness Risk
In a major development, the U.S. Food & Drug Administration announced on Nov. 9 that it would require labels on all GLP-1 drugs to be updated to warn users of a potentially heightened risk of developing non-arteritic anterior ischemic optic neuropathy (NAION).
This condition, which occurs when blood flow to the optic nerve is reduced, can result in sudden, permanent vision loss.
While very rare, the condition being added to GLP-1 labels is a potentially seismic development for hundreds of Ozempic lawsuits already filed by people who say they developed NAION, and that GLP-1 manufacturers should have warned them of the risk.
The FDA-mandated label update could help to bolster that argument as new lawsuits continue to be filed.
Social Media Addiction Trial Ends Following Settlements
A closely watched social media addiction trial ended ahead of opening statements at the start of November because the companies behind Facebook, Instagram and Snapchat agreed to settlements with two teens.
The trial had been set to focus on claims that the popular platforms are designed to intentionally addict users, and that the teens at the center of the case developed serious mental health issues as a result.
Those settlement agreements came as thousands of other social media addiction lawsuits remain pending in both federal and state court. So far, only one individual case has completed a trial, and it ended with Meta and YouTube being ordered to pay a combined $6 million to a woman who said she used their platforms from a young age and developed severe mental health issues.
In recent months, the social media giants have routinely reached settlements in cases as they approach trial, but have not yet agreed to a global settlement for the thousands of active lawsuits.
Bayer Wins Key Roundup Lawsuit Trial as Settlement Decision Looms
In a blow for the future of Roundup lawsuits, Bayer has won the first case to advance to trial since a landmark Supreme Court decision.
Earlier this year, the court essentially wiped out the failure-to-warn claims that were central to cases claiming that the popular weed killer’s manufacturer didn’t warn users of a cancer risk.
The latest trial was instead built around design defect claims, but a Missouri jury unanimously sided with Bayer.
That verdict comes as the company is also awaiting approval of a $7.25 billion Roundup settlement. Bayer’s CEO recently said that he expected the deal to be finalized before Christmas.
The settlement, which could largely resolve the Roundup litigation, has been controversial. Some law firms representing people with lawsuits have argued that it does not provide nearly enough money to compensate tens of thousands of people who say they developed cancer after using the weed killer.